Compare · ACHV vs IDXX
ACHV vs IDXX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.33B, about 51.5x ACHV ($840.7M).
- Over the past year, ACHV is up 163.3% and IDXX is down 14.2% - ACHV leads by 177.6 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- IDXX has more recent analyst coverage (23 ratings vs 10 for ACHV).
- Company
- Achieve Life Sciences Inc.
- IDEXX Laboratories Inc.
- Price
- -
- -
- Market cap
- $840.7M
- $43.33B
- 1M return
- +32.52%
- -1.10%
- 1Y return
- +163.34%
- -14.24%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 6
- 6
- Recent ratings
- 10
- 23
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest ACHV
- Director Stewart Richard Alistair sold $175,177 worth of shares (20,626 units at $8.49), decreasing direct ownership by 9% to 208,249 units (SEC Form 4)
- Morgan Stanley initiated coverage on Achieve Life Sciences with a new price target
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards
- SEC Form 4 filed by Director Sellig Thomas
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Royston Aaron
Latest IDXX
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Second Quarter Results
- Director Hooley Joseph L was granted 49 shares, increasing direct ownership by 18% to 325 units (SEC Form 4)
- IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
- IDEXX Laboratories to Release 2026 Second Quarter Financial Results
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.